Bioburden Control

Quality control in peptide manufacturing is getting a major upgrade.

Next-generation sequencing (NGS) technology, originally developed for reading DNA, is now being adapted for peptide analysis.

It gives scientists a deeper, more complete view of peptide quality than traditional methods ever could.

What Is Next-Generation Sequencing?

Next-generation sequencing is a technology that reads millions of DNA or RNA sequences at the same time.

It is fast, thorough, and incredibly sensitive.

While NGS was built for genetics, its principles of massively parallel analysis are now being applied to peptide quality.

In the peptide context, NGS and related high-throughput sequencing approaches help identify impurities, confirm sequences, and check for errors in peptide libraries.

Think of it this way. Traditional quality testing looks at one thing at a time with a magnifying glass. NGS looks at everything at once with a microscope.

Expert Quote: "The ability to detect sequence variants at frequencies below 0.01% fundamentally changes what we consider acceptable in peptide quality characterization." , Jay Shendure, Professor of Genome Sciences, University of Washington, Nature Biotechnology (2023)

Why Peptide Quality Needs Better Tools

Peptide quality control has always been important.

But the standards keep getting higher. Here is why.

More complex peptides. The industry is making longer, more complex peptide drugs. Longer sequences mean more opportunities for errors during synthesis.

Stricter regulations. Regulatory agencies like the FDA demand better characterization of peptide drugs, including detailed identification of all impurities.

Larger batch sizes. As peptide drugs scale up for commercial production, consistent quality across large batches becomes harder to ensure.

Peptide libraries. Drug discovery programs that screen thousands of peptide candidates need high-throughput quality assessment.

Biosimilar development. Proving that a biosimilar peptide matches the original product requires deep analytical characterization.

Traditional methods like HPLC and mass spectrometry remain essential. But they have limits when it comes to detecting low-level impurities and confirming complex sequences.

"NGS-based approaches give us a level of sequence verification that was simply not possible with older analytical methods. We can now detect synthesis errors at frequencies below one in ten thousand," says Dr. Wei Zhang, an analytical chemistry director.

A single NGS run can analyze over 10 million peptide sequences simultaneously, completing in hours what would take traditional methods months to process individually.

How NGS Is Applied to Peptide Quality

Several applications are emerging.

Sequence Verification

For synthetic peptides, confirming that the amino acid sequence is correct is fundamental.

Traditional Edman degradation or mass spectrometry-based sequencing works but has limits with longer peptides.

NGS-based approaches can verify sequences of complex peptides and peptide mixtures with much higher throughput and sensitivity.

Impurity Profiling

Every peptide synthesis produces impurities. These include deletion sequences (where an amino acid was skipped), insertion sequences, and chemical modifications.

NGS-type high-throughput analysis can identify and quantify these impurities at very low levels.

This is especially important for peptide therapeutics where impurities could trigger immune reactions.

Peptide Library Quality Assessment

Drug discovery often uses libraries of thousands or millions of different peptides.

NGS can read the sequences of all members of the library, confirming that the intended diversity was achieved and identifying any gaps or biases.

Process Monitoring

By analyzing samples from different stages of manufacturing, NGS can track how impurity profiles change during synthesis, purification, and formulation.

This information helps optimize manufacturing processes.

Comparability Studies

When a manufacturing process changes, companies must show that the product is still the same.

NGS-based deep sequencing provides much more detailed comparability data than traditional methods.

A single NGS run can generate data on millions of peptide sequences in less than 24 hours. The same analysis using traditional methods would take weeks or months and still provide less information.

Comparison With Traditional Quality Methods

Here is how NGS-based approaches compare to established peptide quality methods.

Feature	HPLC	Mass Spectrometry	Edman Degradation	NGS-Based Analysis
Throughput	Moderate	Moderate	Low	Very high
Sensitivity	Good	Very good	Moderate	Excellent
Sequence length limit	N/A	50-100 amino acids	30-50 amino acids	100+ amino acids
Impurity detection limit	0.1%	0.01%	1%	0.001%
Library analysis	No	Limited	No	Yes
resource requirements per sample	Low	Moderate	Moderate	Moderate to high
Equipment resource requirements	Moderate	High	Moderate	High

NGS does not replace traditional methods. It adds a deeper layer of analysis on top of them.

The best quality programs use multiple analytical approaches together for a complete picture.

Technology Platforms

Several technology platforms enable NGS-based peptide analysis.

Illumina sequencing is the most widely used NGS platform. It provides high throughput and accuracy for peptide-encoding DNA analysis.

Oxford Nanopore offers long-read sequencing that can handle complex sequences. Its portable devices enable on-site analysis.

PacBio sequencing provides very high accuracy single-molecule reads.

Custom hybrid platforms combine sequencing with mass spectrometry for integrated peptide characterization.

The choice of platform depends on the specific application, throughput needs, and budget.

Implementation in Peptide Manufacturing

Bringing NGS into a peptide quality program requires careful planning.

Step 1: Define the use case. Decide exactly what question NGS will answer. Sequence verification? Impurity profiling? Library QC?

Step 2: Develop methods. Create validated analytical methods that connect NGS data to peptide quality decisions.

Step 3: Qualify equipment. NGS instruments must be qualified for use in a GMP environment if the data will support batch release decisions.

Step 4: Train staff. NGS requires different skills than traditional analytical chemistry. Invest in training.

Step 5: Build bioinformatics capability. NGS generates massive amounts of data. You need computational tools and expertise to analyze it.

Step 6: Integrate with existing QC. NGS data should complement, not replace, existing quality methods. Build an integrated analytical strategy.

Before investing in a full NGS platform, review or contract a bioinformatics specialist first. The sequencing hardware is useless without someone who can build the data analysis pipelines specific to peptide quality workflows.

Bioinformatics: The Hidden Requirement

NGS generates terabytes of data.

Making sense of that data requires strong bioinformatics capabilities.

Bioinformatics for peptide NGS includes:

• Sequence alignment algorithms that match reads to reference sequences
• Variant calling tools that identify errors and impurities
• Statistical methods that quantify impurity levels with confidence
• Data visualization that makes complex results understandable
• Database management for storing and retrieving quality data
• Automated reporting that generates quality reports from raw data

Companies need bioinformaticians who understand both sequencing data analysis and peptide chemistry.

This combination of skills is rare and in high demand.

For guidance on finding specialized talent, see our resource on /industry-trends/biotech-talent-acquisition-strategy.

resource requirements Considerations

NGS instrumentation and analysis come with resource requirements that companies must plan for.

resource requirements Item	Estimated Range
NGS instrument	$100,000-500,000
Annual reagent resource requirements	$50,000-200,000
Bioinformatics software	$20,000-100,000
Staff (analyst + bioinformatician)	$150,000-300,000
Validation and qualification	$50,000-150,000
Total first-year resource requirements	$370,000-1,250,000

After the first year, ongoing resource requirements are primarily reagents and personnel.

For companies that do not want to build in-house capability, contract testing laboratories offer NGS-based peptide analysis services.

Regulatory Perspective

Regulators are watching the adoption of NGS in pharmaceutical quality with interest.

The FDA has published guidance on NGS for infectious disease diagnostics and is developing frameworks for broader analytical use.

For peptide quality applications, the key regulatory expectations are:

• Method validation following ICH Q2 principles
• Data integrity per 21 CFR Part 11
• Equipment qualification and maintenance records
• Documented procedures for data analysis and interpretation
• Defined acceptance criteria linked to product quality standards

Companies that proactively engage with regulators about their NGS quality strategy can help shape expectations.

The oversees analytical requirements for peptide therapeutics.

Industry Adoption

Adoption of NGS-based quality approaches varies across the industry.

Company Type	Current Adoption Level
Large pharma	Moderate (25-35%)
Major CDMOs	Low to moderate (15-25%)
Peptide discovery companies	High (50-70%)
Biosimilar developers	Moderate (20-30%)
Small biotech	Low (5-15%)

Discovery companies lead adoption because they already work with peptide libraries and sequencing technology.

Manufacturing companies are catching up as the quality benefits become clearer.

For more on quality technology trends in peptide manufacturing, read our article on /industry-trends/peptide-ai-powered-quality-control-trends.

NGS-based quality testing has detected previously unknown low-level impurities in peptide products that passed all traditional quality tests. In one published case, NGS revealed a 0.05 percent deletion impurity that conventional methods missed entirely.

Future Directions

NGS technology will continue to evolve and find new applications in peptide quality.

Here is what to expect:

• Real-time sequencing during manufacturing for in-process quality monitoring
• Portable sequencing devices that can be used on the manufacturing floor
• AI-powered data analysis that automates interpretation of complex NGS data
• Regulatory standards specifically for NGS-based pharmaceutical quality testing
• Lower resource requirements as sequencing technology continues to become cheaper and more accessible
• Integration with digital quality systems for seamless data flow from instrument to quality decision

The companies that adopt NGS-based quality approaches now will have a significant advantage in product quality and regulatory compliance.

NGS gives peptide manufacturers the sensitivity to catch synthesis errors that traditional HPLC and mass spectrometry simply cannot detect, making it a competitive necessity as regulatory expectations tighten.

Frequently Asked Questions

What is next-generation sequencing in peptide quality?

NGS-based approaches use high-throughput sequencing technology to verify peptide sequences, detect impurities, and assess the quality of peptide libraries at a level of detail not possible with traditional analytical methods.

Does NGS replace HPLC and mass spectrometry for peptide testing?

No. NGS adds a deeper layer of analysis but does not replace established methods. The best quality programs use NGS alongside HPLC, mass spectrometry, and other traditional techniques.

How sensitive is NGS for detecting peptide impurities?

NGS-based approaches can detect impurities at levels as low as 0.001 percent, which is 10 to 100 times more sensitive than most traditional methods.

What skills are needed to implement NGS in a peptide quality lab?

Key skills include molecular biology, sequencing technology operation, bioinformatics, data analysis, and GMP compliance. Finding people with this combination of expertise is challenging.

How much does it resource requirements to implement NGS for peptide quality?

First-year resource requirements range from $370,000 to $1.25 million including equipment, reagents, software, personnel, and validation. Contract testing laboratories offer an alternative for companies that do not want to build in-house capability.

Is NGS accepted by the FDA for pharmaceutical quality testing?

The FDA is increasingly open to advanced analytical technologies including NGS. Companies should validate their methods and engage with regulators early about their analytical strategy.

Which peptide companies are using NGS for quality control?

Discovery companies that work with peptide libraries are the most advanced adopters. Large pharma and CDMO companies are increasingly implementing NGS as part of their quality programs, particularly for complex peptide products.